マバコキシブ

使用用途

• Any
• Pain and inflammation associated with degenerative joint disease in dogs aged 12 months or more in cases where continuous treatment exceeding one month is indicated
• Pain and inflammation associated with degenerative joint disease (osteoarthritis)

投与方法

考えられる副作用

• Inappetence
• Diarrhea
• Vomiting
• Depression
• Renal toxicity
• Gastrointestinal ulceration
• Gastrointestinal ulceration or bleeding
• Vomiting and diarrhoea
• Renal toxicity (especially if dehydrated or hypotensive)
• Hepatic accumulation (in poor metabolizers)
• Theoretical risk of precipitating cardiac failure

注意事項と禁忌

• Dogs less than 12 months of age
• Dogs less than 5 kg body weight
• Gastrointestinal disorders including ulceration and bleeding
• Evidence of a hemorrhagic disorder
• Impaired renal or hepatic function
• Cardiac insufficiency
• Hypersensitivity to mavacoxib, sulfonamides, or excipients
• Pregnant, breeding, or lactating animals
• Dehydrated, hypovolemic, or hypotensive animals
• Dehydrated, hypovolaemic, or hypotensive patients
• Gastrointestinal disease or ulceration
• Blood clotting disorders
• Liver disease (prolongs metabolism and causes accumulation)
• Renal disease (requires careful evaluation, generally avoid)
• Pregnant or lactating animals
• Dogs < 12 months of age
• Dogs < 5 kg body weight
• Cats
• Do not use concomitantly with glucocorticoids or other NSAIDs. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib. Avoid use in any dehydrated, hypovolemic, or hypotensive animal, as there is a potential risk of increased renal toxicity. Concurrent administration of potentially nephrotoxic medicinal products should be avoided. Animals should not become dehydrated when receiving this or other NSAIDs.

薬物相互作用

• ACE Inhibitors (e.g., enalapril, benazepril): NSAIDs can reduce effects on blood pressure and potentially reduce renal blood flow, increasing the risk for renal injury.
• Aspirin: May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Long washout periods are warranted when switching.
• Corticosteroids (e.g., prednisone): May increase the risk of gastrointestinal toxicity (ulceration, bleeding, vomiting, diarrhea). Concurrent use is contraindicated.
• Digoxin: NSAIDs may increase serum levels of digoxin.
• Fluconazole: May increase plasma levels of mavacoxib (extrapolated from celecoxib data in humans).
• Furosemide: NSAIDs may reduce saluretic and diuretic effects.
• Methotrexate: Serious toxicity has occurred when NSAIDs have been used concomitantly; use together with extreme caution.
• Nephrotoxic Drugs (e.g., aminoglycosides, amphotericin B): May enhance the risk of nephrotoxicity development.
• Other NSAIDs: May increase the risk of gastrointestinal toxicity. Do not administer other NSAIDs within 1 month of the last administration of mavacoxib.
• Glucocorticoids: Increased risk of severe gastrointestinal ulceration and bleeding.
• Aminoglycosides: Increased risk of nephrotoxicity.
• Other nephrotoxic agents: Synergistic risk of acute kidney injury.

よくある質問